Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1996 2
1998 3
1999 3
2001 2
2002 1
2003 1
2004 1
2005 3
2006 1
2007 1
2008 1
2009 2
2010 2
2011 1
2012 3
2013 4
2014 4
2015 4
2016 2
2017 7
2018 4
2019 3
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for aris basis
Your search for Aris Batis retrieved no results
Aldose reductase inhibitors of plant origin.
Veeresham C, Rama Rao A, Asres K. Veeresham C, et al. Phytother Res. 2014 Mar;28(3):317-33. doi: 10.1002/ptr.5000. Epub 2013 May 15. Phytother Res. 2014. PMID: 23674239 Review.
A number of synthetic AR inhibitors (ARIs) including tolrestat and sorbinil have been developed, but all of these suffer from drawbacks such as poor permeation and safety issues. ...Phytochemicals such as quercetin, kaempferol and ellagic acid are found to be the most prom …
A number of synthetic AR inhibitors (ARIs) including tolrestat and sorbinil have been developed, but all of these suffer from drawbac …
Diminishing benefits of urban living for children and adolescents' growth and development.
NCD Risk Factor Collaboration (NCD-RisC). NCD Risk Factor Collaboration (NCD-RisC). Nature. 2023 Mar;615(7954):874-883. doi: 10.1038/s41586-023-05772-8. Epub 2023 Mar 29. Nature. 2023. PMID: 36991188 Free PMC article.
Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the height and body-mass index (BMI) of children and adolescents aged 5-19 years on the basis of rural and urban place of residence in 200 …
Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the he …
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
Conde-Estévez D, Henríquez I, Muñoz-Rodríguez J, Rodriguez-Vida A. Conde-Estévez D, et al. Expert Opin Drug Metab Toxicol. 2022 Sep;18(9):601-613. doi: 10.1080/17425255.2022.2122812. Epub 2022 Sep 16. Expert Opin Drug Metab Toxicol. 2022. PMID: 36111393 Review.
INTRODUCTION: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are frequently poly-medicated due to age-related and androgen deprivation therapy (ADT)-derived comorbidities. In high-risk patients, androgen receptor inhibitors (ARIs) have shown to …
INTRODUCTION: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are frequently poly-medicated due to age-related an …
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Zenon GJ 3rd, Abobo CV, Carter BL, Ball DW. Zenon GJ 3rd, et al. Clin Pharm. 1990 Jun;9(6):446-57. Clin Pharm. 1990. PMID: 2114249 Review.
Reviewed are (1) the biochemical basis and pathophysiology of diabetic complications and (2) the structure-activity relationships, pharmacology, pharmacokinetics, clinical trials, and adverse effects of aldose reductase inhibitors (ARIs). ...The adverse effects of …
Reviewed are (1) the biochemical basis and pathophysiology of diabetic complications and (2) the structure-activity relationships, ph …
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.
Aris M, Mordoh J, Barrio MM. Aris M, et al. Front Immunol. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024. eCollection 2017. Front Immunol. 2017. PMID: 28970830 Free PMC article. Review.
In this review, we will go through the role of promising monoclonal antibodies in cancer immunotherapy with immunomodulatory function, especially blocking of the inhibitory immune checkpoints CTLA-4 and PD-1, in combination with different immunotherapeutic strategies such as vacc …
In this review, we will go through the role of promising monoclonal antibodies in cancer immunotherapy with immunomodulatory function, espec …
Population-based hospitalization burden estimates for respiratory viruses, 2015-2019.
Zimmerman RK, Balasubramani GK, D'Agostino HEA, Clarke L, Yassin M, Middleton DB, Silveira FP, Wheeler ND, Landis J, Peterson A, Suyama J, Weissman A, Nowalk MP. Zimmerman RK, et al. Influenza Other Respir Viruses. 2022 Nov;16(6):1133-1140. doi: 10.1111/irv.13040. Epub 2022 Aug 22. Influenza Other Respir Viruses. 2022. PMID: 35996836 Free PMC article.
BACKGROUND: Acute respiratory infections (ARIs) result in millions of illnesses and hundreds of thousands of hospitalizations annually in the United States. ...CONCLUSIONS: These virus-specific ARI population-based hospital burden estimates showed significant non-influenza …
BACKGROUND: Acute respiratory infections (ARIs) result in millions of illnesses and hundreds of thousands of hospitalizations annuall …
Drugs designed to maintain the transparence of the ocular lens.
Chanalet L, Lapalus P. Chanalet L, et al. Fundam Clin Pharmacol. 1994;8(4):322-41. doi: 10.1111/j.1472-8206.1994.tb00810.x. Fundam Clin Pharmacol. 1994. PMID: 7851838 Review.
ARIs have shown efficacy in slowing down and preventing the progression of experimental sugar cataracts; sorbinil can partially reverse the very early morphological signs of sugar cataract. Sorbinil and imirestat have also demonstrated anti-oxidant properties. ARIs …
ARIs have shown efficacy in slowing down and preventing the progression of experimental sugar cataracts; sorbinil can partially rever …
Noninvasive treatment of benign prostatic hyperplasia. Where do we stand in 2005.
Al-Ansari AA, Shokeir AA. Al-Ansari AA, et al. Saudi Med J. 2006 Mar;27(3):299-304. Saudi Med J. 2006. PMID: 16532087 Review.
Amongst available therapies, only 5 ARIs have been shown to reduce the risk of acute urine retention AUR and BPH-related surgery compared to placebo. The Medical Therapy of Prostatic Symptoms MTOPS Study provides rational basis for combined alpha-blockers plus 5 …
Amongst available therapies, only 5 ARIs have been shown to reduce the risk of acute urine retention AUR and BPH-related surgery comp …
Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS, Fleshner NE, Thompson IM. Rittmaster RS, et al. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200641 Review.
This review addresses the evidence and issues surrounding prostate cancer risk reduction. OBJECTIVE: The scientific basis, therapeutic approach, and risks and benefits of prostate cancer prevention are reviewed. ...The greatest benefit arises from decreasing the amount of …
This review addresses the evidence and issues surrounding prostate cancer risk reduction. OBJECTIVE: The scientific basis, therapeuti …
Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?
Hollingsworth JM, Wei JT. Hollingsworth JM, et al. Curr Opin Urol. 2010 Jan;20(1):1-6. doi: 10.1097/MOU.0b013e3283336f96. Curr Opin Urol. 2010. PMID: 19881352 Review.
BACKGROUND: Alpha1-adrenergic antagonists relieve lower urinary tract symptoms related to benign prostatic hyperplasia. 5alpha-Reductase inhibitors (ARIs) can halt the disease's progression. To assess whether their combined use had an additive benefit, we identified and su …
BACKGROUND: Alpha1-adrenergic antagonists relieve lower urinary tract symptoms related to benign prostatic hyperplasia. 5alpha-Reductase inh …
62 results